WEBINAR RECORDING AVAILABLE - WATCH ON DEMAND

Building a digital foundation for patient-centric trials

The evolution of clinical trial design has highlighted the need for better data management and a more holistic digital approach that connects sponsors, sites, and patients for seamless execution and data flow. Join this webinar to hear how LEO Pharma is adopting a connected digital trial solution to bring innovative treatments to patients faster while maintaining the highest levels of data accuracy, regulatory compliance, and patient safety.

In this webinar, you will hear:
  • How LEO Pharma is building a foundation for digital clinical trials
  • Strategies for managing clinical data centrally
  • Considerations for optimizing the patient journey and site relationship
  • Practical approaches to improving data sharing and collaboration
  • How a holistic digital platform could reduce trial costs and timelines
watch now
Watch the webinar on demand
Tim Davis

Tim Davis

VP Strategy, MyVeeva for Patients, Veeva Systems

Tim Davis has over 25 years of experience working in the Life Sciences industry from a pharmaceutical company, CRO, and technology vendor perspective.

Most notably he was the Founder & CEO of Exco InTouch Ltd, a patient engagement and eCOA mobile application provider, which he scaled through to a successful trade sale and exit in 2016.

Tim is currently Vice President of Strategy at Veeva Systems. His primary focus is on the strategic development of MyVeeva for Patients, a patient-facing application suite.

Stephen Lutsch

Stephen Lutsch

Director, Head of Revolutionize Clinical Trials, LEO Pharma

Stephen is part of LEO Pharma’s Global Clinical Operations leadership team and is tasked with driving radical innovation to help achieve LEO’s ambitious goals. He leads the Veeva digital partnership and helps put in place the critical technical, data, and automation foundations for hybrid decentralized clinical trials, where they plan to run fully decentralized and hybrid phase IV trials that will mirror closely Phase 2-3 trial designs. These critical operational and regulatory learnings should accelerate efforts to scale DCTs across their portfolio. Stephen lives north of Copenhagen, Denmark with his wife and three children.

Arsalan Arif
moderator

Arsalan Arif

Founder & publisher, endpoints news

Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.